Drugs & Targets FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL September 01, 2017Vol.43 No.32
Drugs & Targets Novartis’s Kymriah becomes first gene therapy to get FDA approval September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves Mylotarg for treatment of acute myeloid leukemia September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves Lynparza (olaparib) tablets for maintenance treatment in ovarian cancer September 01, 2017Vol.43 No.32
Drugs & Targets Ocugen gets Orphan Drug designation for ocular graft vs. host disease September 01, 2017Vol.43 No.32
Drugs & Targets FDA acts to remove unproven treatment used in ‘stem cell’ centers September 01, 2017Vol.43 No.32
Drugs & Targets Enasidenib, companion diagnostic get FDA approval for relapsed or refractory AML August 04, 2017Vol.43 No.31
Drugs & Targets Vyxeos gets FDA approval for first treatment for types of poor-prognosis AML August 04, 2017Vol.43 No.31
Drugs & Targets Opdivo gets FDA accelerated approval for MSI-H/dMMR colorectal cancer August 04, 2017Vol.43 No.31
